Display Settings:

Format

Send to:

Choose Destination
Gut. 2007 Sep;56(9):1181-3.

Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Author information

  • Department of Medicine and Clinical Pharmacology, University of Chicago Hospital, 5841 S. Maryland Ave., MC 4076, Chicago, IL 60637, USA. shanauer@uchicago.edu

Abstract

Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

Comment on

PMID:
17698862
[PubMed - indexed for MEDLINE]
PMCID:
PMC1954967
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk